Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
P/S ratio for Armata Pharmaceuticals, Inc. (ARMP)
P/S ratio as of 2023: 25.81
According to Armata Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 25.81. At the end of 2022 the company had a P/S ratio of 7.72.
P/S ratio history for Armata Pharmaceuticals, Inc. from 1993 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 25.81 |
| 2022 | 7.72 |
| 2021 | 29.52 |
| 2020 | 59.53 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 56.10 |
| 2016 | 16.65 |
| 2015 | 45.34 |
| 2014 | 93.89 |
| 2013 | 155.69 |
| 2012 | 12.66 |
| 2008 | 0.50 |
| 2007 | 2.46 |
| 2006 | 5.33 |
| 2005 | 6.10 |
| 2004 | 12.76 |
| 2003 | 125.24 |
| 2002 | 13.26 |
| 2001 | 88.27 |
| 2000 | 309.96 |
| 1999 | 260.79 |
| 1998 | 67.97 |
| 1997 | 824.63 |
| 1996 | 449.35 |
| 1995 | 9029.48 |
| 1994 | 1102.50 |
| 1993 | 124920.34 |